Yes true-To The Moon - Tiger Brokers Online Investing Community - To The Moon

2
Comment
Favorite

DavidLoh
2021-06-18

Yes true

Tesla Partner CureVac Says Will Find 'Sweet Spot' For COVID-19 Vaccine Despite Disappointing Data

CureVac N.V.’s Chief Financial Officer Pierre Kemula is optimistic its COVID-19 vaccine could still be offered to certain age groups or as a booster, the Financial Timesreportedon Thursday.What Happened:Kemula told FT the German vaccine developer is still hopeful the jab could be offered to certain age groups or as a booster after data from CureVac’s late-stage trial of its international first-generation vaccine candidateshowed that it had only47% efficacy.“There is a lot of need for vaccines ou

Tesla Partner CureVac Says Will Find 'Sweet Spot' For COVID-19 Vaccine Despite Disappointing Data

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

2

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":166275570,"tweetId":"166275570","gmtCreate":1624014944490,"gmtModify":1703826588627,"author":{"id":3574387511172860,"idStr":"3574387511172860","authorId":3574387511172860,"authorIdStr":"3574387511172860","name":"DavidLoh","avatar":"https://static.tigerbbs.com/6e241027ed98c20cf6994afaebda97a3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Yes true</p></body></html>","htmlText":"<html><head></head><body><p>Yes true</p></body></html>","text":"Yes true","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/166275570","repostId":1118915240,"repostType":2,"repost":{"id":"1118915240","pubTimestamp":1624003162,"share":"https://www.laohu8.com/m/news/1118915240?lang=&edition=full","pubTime":"2021-06-18 15:59","market":"us","language":"en","title":"Tesla Partner CureVac Says Will Find 'Sweet Spot' For COVID-19 Vaccine Despite Disappointing Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1118915240","media":"benzinga","summary":"CureVac N.V.’s Chief Financial Officer Pierre Kemula is optimistic its COVID-19 vaccine could still be offered to certain age groups or as a booster, the Financial Timesreportedon Thursday.What Happened:Kemula told FT the German vaccine developer is still hopeful the jab could be offered to certain age groups or as a booster after data from CureVac’s late-stage trial of its international first-generation vaccine candidateshowed that it had only47% efficacy.“There is a lot of need for vaccines ou","content":"<p><b>CureVac N.V.’s</b>&nbsp;Chief Financial Officer Pierre Kemula is optimistic its COVID-19 vaccine could still be offered to certain age groups or as a booster, the Financial Timesreportedon Thursday.</p>\n<p><b>What Happened:</b>Kemula told FT the German vaccine developer&nbsp;is still hopeful the jab could be offered to certain age groups or as a booster after data from CureVac’s late-stage trial of its international first-generation vaccine candidateshowed that it had only47% efficacy.</p>\n<p>“There is a lot of need for vaccines out there,” Kemula said, adding it will work with the agencies to find a “sweet spot” for the vaccine usage, as per the report.</p>\n<p><b>Why It Matters:</b>Expectations were running high for CureVac, in which the German government bought a 23% stake to allay concerns it could move to the United States. CureVac’s vaccine program disappointment comes at a time when a handful of vaccines are already in the market through the emergency authorization route.</p>\n<p>The U.S. Food and Drug Administration has recently revised vaccine review guidelines, deciding not to entertain emergency use applications. Instead, the agency is now contemplating review only through the full approval process route, necessitating more detailed data.</p>\n<p>CureVac has acollaboration&nbsp;with&nbsp;<b>Tesla Inc</b>&nbsp;for vaccine printers. In April, Elon Musk in a tweet&nbsp;suggested CureVac was “a few months away from regulatory approval,” but deleted it soon after.</p>\n<p><b>Price Action:</b>CureVac shares dived 39% to close at $57.83 on Thursday.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Partner CureVac Says Will Find 'Sweet Spot' For COVID-19 Vaccine Despite Disappointing Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Partner CureVac Says Will Find 'Sweet Spot' For COVID-19 Vaccine Despite Disappointing Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 15:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/06/21620566/tesla-partner-curevac-says-will-find-sweet-spot-for-covid-19-vaccine-despite-disappointing-data><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CureVac N.V.’s Chief Financial Officer Pierre Kemula is optimistic its COVID-19 vaccine could still be offered to certain age groups or as a booster, the Financial Timesreportedon Thursday.\nWhat ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/06/21620566/tesla-partner-curevac-says-will-find-sweet-spot-for-covid-19-vaccine-despite-disappointing-data\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","CVAC":"CureVac B.V."},"source_url":"https://www.benzinga.com/general/biotech/21/06/21620566/tesla-partner-curevac-says-will-find-sweet-spot-for-covid-19-vaccine-despite-disappointing-data","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118915240","content_text":"CureVac N.V.’s Chief Financial Officer Pierre Kemula is optimistic its COVID-19 vaccine could still be offered to certain age groups or as a booster, the Financial Timesreportedon Thursday.\nWhat Happened:Kemula told FT the German vaccine developer is still hopeful the jab could be offered to certain age groups or as a booster after data from CureVac’s late-stage trial of its international first-generation vaccine candidateshowed that it had only47% efficacy.\n“There is a lot of need for vaccines out there,” Kemula said, adding it will work with the agencies to find a “sweet spot” for the vaccine usage, as per the report.\nWhy It Matters:Expectations were running high for CureVac, in which the German government bought a 23% stake to allay concerns it could move to the United States. CureVac’s vaccine program disappointment comes at a time when a handful of vaccines are already in the market through the emergency authorization route.\nThe U.S. Food and Drug Administration has recently revised vaccine review guidelines, deciding not to entertain emergency use applications. Instead, the agency is now contemplating review only through the full approval process route, necessitating more detailed data.\nCureVac has acollaboration with Tesla Inc for vaccine printers. In April, Elon Musk in a tweet suggested CureVac was “a few months away from regulatory approval,” but deleted it soon after.\nPrice Action:CureVac shares dived 39% to close at $57.83 on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":246,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}